JSK BioMed Unveils Mirajet Forte at ASLS TOKYO 2026

Needle-free drug-delivery device introduced to Japanese clinicians with partner Fotona, as local market expansion continues

JSK BioMed#\
Mirajet Forte
Fotona
needle-free drug delivery
needleless injection
ASLS TOKYO 2026
Japan aesthetic medicine
Er:YAG laser
skin booster
Fotona laser XS-Dynamis
medical device export
K-Medical
Grand Prince Hotel Shin Takanawa
regenerative treatment
Fotona Japan

이원국 기자

26-07-12

JSK BioMed partnered with global medical laser company Fotona (Fotona d.o.o) to present its needle-free drug-delivery device "Mirajet Forte" to local clinicians at ASLS TOKYO 2026, held at the Grand Prince Hotel Shin Takanawa in Tokyo, Japan.

■ International Conference Brings Together Korean, Japanese Aesthetic Medicine Experts

JSK BioMed announced on the 10th that it partnered with global medical laser company Fotona (Fotona d.o.o) to present its needle-free drug-delivery device "Mirajet Forte" to local clinicians at ASLS TOKYO 2026, held at the Grand Prince Hotel Shin Takanawa in Tokyo. ASLS TOKYO 2026 is an international academic event where Korean and Japanese aesthetic medicine specialists share the latest clinical experience and technology trends. This year's program covered skin boosters, regenerative treatments, energy-based devices (EBD), lifting, and pigmentation and skin-texture improvement.

■ Fotona Partnership Expands Reach Among Japanese Clinicians

JSK BioMed took part in the event alongside its global partner Fotona to introduce Mirajet Forte and broaden its network among Japanese medical professionals. Mirajet Forte is currently sold in Japan through Fotona Japan, and the event served as an opportunity to publicize the two companies' partnership and their strategy for expanding in the Japanese market.

■ Needle-Free Drug Delivery Powered by Laser Pressure

mirajet is JSK BioMed's flagship medical device, built on laser pressure-based needle-free drug-delivery technology. It is designed to deliver medication into the skin in microjet form using the instantaneous pressure generated by a 2940nm Er:YAG laser. Mirajet Forte is a high-power version that incorporates the Fotona laser XS-Dynamis developed by Fotona.

■ Strong Local Interest in Clinical Applications

At the event, Japanese clinicians and aesthetic medicine professionals from across Asia inquired about and consulted on the product. According to the company, interest was especially strong around Fotona Japan's sales system and the device's real-world clinical applicability.

■ "Strengthening Our Foothold in Japan, Continuing Global Expansion"

A JSK BioMed official said, "ASLS TOKYO 2026 was a meaningful opportunity to directly introduce Japanese clinicians to Mirajet Forte's technology and clinical potential together with our global partner Fotona." The official added, "Building on our cooperation with Fotona, we will strengthen our position in the Japanese market and continue expanding into overseas markets."

FAQ

What kind of company is JSK BioMed?

JSK BioMed is a Korean medical device company that develops needle-free drug-delivery devices. It has partnered with global medical laser company Fotona to expand into overseas markets.

What is Mirajet Forte?

Mirajet Forte is a needle-free drug-delivery device that uses laser pressure to deliver medication into the skin without a needle. It incorporates Fotona's high-power Fotona laser XS-Dynamis platform.

What is the core technology behind mirajet?

It uses the instantaneous pressure generated by a 2940nm Er:YAG laser to deliver medication into the skin in microjet form. Because no needle is used, it is designed to reduce pain and infection risk.

What kind of event is ASLS TOKYO 2026?

It is an international academic event where Korean and Japanese aesthetic medicine specialists share the latest clinical experience and technology trends. This year's topics included skin boosters, regenerative treatments, EBD, lifting, and pigmentation and skin-texture improvement.

How can Mirajet Forte be purchased in Japan?

It is currently sold in Japan through Fotona Japan. Participating in ASLS TOKYO 2026 gave JSK BioMed a chance to introduce this sales structure directly to local clinicians.

What does the Fotona partnership mean for JSK BioMed?

Through its cooperation with global medical laser company Fotona, JSK BioMed is broadening its reach into Japan and other Asian aesthetic medicine markets. The company said the event helped publicize the partnership locally.

How might this participation affect future business expansion?

JSK BioMed said it plans to strengthen its position in the Japanese market and continue expanding overseas, building on its cooperation with Fotona. Strong interest from clinicians across Asia is seen as a positive factor for future growth.